To maintain profits in the face of rising development costs and slow drug pipelines, big pharmaceutical firms are trying to cut back. Heidi Ledford examines how GlaxoSmithKline has tried to adapt.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Ledford, H. When there's no room to grow. Nature 454, 144–145 (2008). https://doi.org/10.1038/454144a
Published:
Issue Date:
DOI: https://doi.org/10.1038/454144a
This article is cited by
-
Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery
Nature Reviews Drug Discovery (2009)